Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.

Employees - 39, CEO - Timothy K. Lu, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -20.89, Piotroski Score(max is 10): 2, Working Capital: $-2758000, Total Assets: $33105000, Retained Earnings: $-375543000, EBIT: -50125000, Total Liabilities: $36506000, Revenue: $55000

AryaFin Target Price - $-0.06 - Current Price $ - Analyst Target Price $